Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00867048
Registration number
NCT00867048
Ethics application status
Date submitted
20/03/2009
Date registered
23/03/2009
Date last updated
4/03/2024
Titles & IDs
Public title
Strategic Timing of Antiretroviral Treatment
Query!
Scientific title
Strategic Timing of AntiRetroviral Treatment
Query!
Secondary ID [1]
0
0
U01AI068641
Query!
Secondary ID [2]
0
0
0603M83587
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
START
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HIV Infection
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Acquired immune deficiency syndrome (AIDS / HIV)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - All licensed antiretroviral medications
Experimental: Early ART - Initiate ART immediately following randomization
Active comparator: Deferred ART - Defer ART until the CD4+ count declines to \<350 cells/cu mm or AIDS develops
Treatment: Drugs: All licensed antiretroviral medications
In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Composite Endpoint of AIDS, Serious Non-AIDS Diagnoses, and All-cause Mortality
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
full follow-up, 9.3 years
Query!
Secondary outcome [1]
0
0
AIDs or AIDs Related Death
Query!
Assessment method [1]
0
0
participant count
Query!
Timepoint [1]
0
0
full follow-up, 9.3 years
Query!
Secondary outcome [2]
0
0
Specific Non-AIDS Diagnoses
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
full follow-up, 9.3 years
Query!
Secondary outcome [3]
0
0
Death, All-cause Mortality
Query!
Assessment method [3]
0
0
Count of participants
Query!
Timepoint [3]
0
0
full follow-up, 9.3 years
Query!
Secondary outcome [4]
0
0
Quality of Life- Mean Change From Baseline in a Visual Analog Scale (VAS) for Perceived Current Health
Query!
Assessment method [4]
0
0
Mean change from baseline of the VAS. This was a single data item where participants self-reported their perceived current state of health on a scale of 0-100 (0=worst possible and 100=best possible).
Query!
Timepoint [4]
0
0
4.5 years
Query!
Secondary outcome [5]
0
0
Transmission Risk Behavior Outcome 1
Query!
Assessment method [5]
0
0
Proportion of participants identifying as men who have sex with men (MSM) engaging in condomless sex with HIV serodifferent partners (CLS-D) at study month 12. Participant completed a self-reported questionnaire on transmission risk behavior during the "past two months" at the month 12 visit following randomization.
Query!
Timepoint [5]
0
0
12 months
Query!
Secondary outcome [6]
0
0
Change in Neurocognitive Function (in a Subset of Participants)
Query!
Assessment method [6]
0
0
Mean change from baseline of the QNPZ-8 score. In the Neurology substudy of START, participants were administered a neuropsychological test battery of 8 tests (grooved peg board, finger tapping, Color Trails 1 and 2, Semantic Verbal Fluency, WAIS III Digit Symbol, HVLT-R Learning, HVLT-R Delayed Recall). Test scores were standardized to z-scores using baseline values as reference such that baseline values had a mean of 0 and standard deviation of 1. Test scores were standardized to z-scores using baseline values as reference such that baseline values had a mean of 0 and standard deviation of 1. Z-scores \> 0 indicate improvement over baseline levels. The quantitative neuropsychological performance z-score (QNPZ-8) was the mean of the z-scores across the the 8 tests. Analyses were by intention-to-treat principles.
Query!
Timepoint [6]
0
0
4.5 years
Query!
Secondary outcome [7]
0
0
Large Artery Elasticity (in a Subset of Participants)
Query!
Assessment method [7]
0
0
Mean change from baseline in large arterial elasticity. In the Arterial Elasticity substudy of START, participants had non-invasive measurements of radial artery blood pressure waveforms recorded at baseline, study months 4, 8, and 12, and then annually. Small arterial elasticity (SAE) and large arterial elasticity (LAE) were derived from analysis of the diastolic pulse waveform. Analyses were by intention-to-treat principles.
Query!
Timepoint [7]
0
0
4.5 years
Query!
Secondary outcome [8]
0
0
Rate of Lung Function Decline (in a Subset of Participants) Among
Query!
Assessment method [8]
0
0
Rate of lung function decline (slope of forced expiratory volume (FEV1)) over follow-up among self-reported smokers at study entry. In the pulmonary substudy of START, participants had post-bronchodilator spirometry measures collected at baseline and annually. Analyses were by intention-to-treat principles.
Query!
Timepoint [8]
0
0
4.5 years
Query!
Secondary outcome [9]
0
0
Changes in Bone Mineral Density (in a Subset of Participants) Measure 1
Query!
Assessment method [9]
0
0
Mean percent change from baseline in bone mineral density at the spine. In the bone mineral density (BMD) substudy of START, participants underwent dual-enery x-ray absorptionmetry (DXA) to measure BMD at the spine and hip at baseline and annually. Analyses were by intention-to-treat principles.
Query!
Timepoint [9]
0
0
4.5 years
Query!
Secondary outcome [10]
0
0
Transmission Risk Behavior Outcome 2
Query!
Assessment method [10]
0
0
Percentage of participants identifying as hetrosexual engaging in condomless sex with HIV serodifferent partners (CLS-D) at study month 12. Participant completed a self-reported questionnaire on transmission risk behavior during the "past two months" at the month 12 visit following randomization.
Query!
Timepoint [10]
0
0
12 month visit
Query!
Secondary outcome [11]
0
0
Small Artery Elasticity (in a Subset of Participants)
Query!
Assessment method [11]
0
0
Mean change from baseline in small arterial elasticity. In the Arterial Elasticity substudy of START, participants had non-invasive measurements of radial artery blood pressure waveforms recorded at baseline, study months 4, 8, and 12, and then annually. Small arterial elasticity (SAE) and large arterial elasticity (LAE) were derived from analysis of the diastolic pulse waveform. Analyses were by intention-to-treat principles.
Query!
Timepoint [11]
0
0
4.5 years
Query!
Secondary outcome [12]
0
0
Rate of Lung Function Decline (in a Subset of Participants) Among Non-smokers
Query!
Assessment method [12]
0
0
Rate of lung function decline (slope of forced expiratory volume (FEV1)) over follow-up among self-reported non-smokers at study entry. In the pulmonary substudy of START, participants had post-bronchodilator spirometry measures collected at baseline and annually. Analyses were by intention-to-treat principles.
Query!
Timepoint [12]
0
0
4.5 years
Query!
Secondary outcome [13]
0
0
Changes in Bone Mineral Density (in a Subset of Participants) Measure 2
Query!
Assessment method [13]
0
0
Mean percent change from baseline in bone mineral density at the spine. In the bone mineral density (BMD) substudy of START, participants underwent dual-enery x-ray absorptionmetry (DXA) to measure BMD at the spine and hip at baseline and annually. Analyses were by intention-to-treat principles.
Query!
Timepoint [13]
0
0
4.5 years
Query!
Eligibility
Key inclusion criteria
INCLUSION CRITERIA:
* Signed informed consent
* HIV infection documented by a plasma HIV RNA viral load, rapid HIV test or any licensed* ELISA test; and confirmed by another test using a different method including but not limited to a rapid HIV test, Western Blot, HIV culture, HIV antigen, or HIV pro-viral DNA at any time prior to study entry.
* Age greater than or equal to 18 years
* Karnofsky performance score greater than or equal to 80 (an indication that the participant can perform normal activities)
* Perceived life expectancy of at least 6 months
* For women of child-bearing potential, willingness to use contraceptives as described in the product information of the ART drugs they are prescribed
* Two CD4+ cell counts greater than 500 cells/mm(3) at least 2 weeks apart within 60 days before randomization
* The term licensed refers to an FDA-approved kit or, for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country. Confirmation of the initial test result must use a test method that is different than the one used for the initial assessment.
EXCLUSION CRITERIA:
* Any previous use of ART or interleukin-2 (IL-2)
* Diagnosis of any clinical AIDS event before randomization (including esophageal candidiasis and chronic Herpes simplex infection)
* Presence of HIV progression such as oral thrush, unexplained weight loss, or unexplained fever
* Cardiovascular event (myocardial infarction, angioplasty, coronary-artery bypass grafting, stroke) within 6 months before randomization
* Non-AIDS-defining cancer, excluding basal and squamous cell skin cancer, within 6 months before randomization
* Dialysis within 6 months before randomization
* Diagnosis of decompensated liver disease before randomization
* Current imprisonment, or compulsory detention (involuntary incarceration) for treatment of a psychiatric or physical illness
* Current pregnancy or breastfeeding (a negative serum or urine pregnancy test is required within 14 days before randomization for women of child-bearing potential)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/04/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/07/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
4688
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Burwood Road General Practice - Burwood
Query!
Recruitment hospital [2]
0
0
East Sydney Doctors - Darlinghurst
Query!
Recruitment hospital [3]
0
0
Holdsworth House Medical Practice - Darlinghurst
Query!
Recruitment hospital [4]
0
0
St. Vincent's Hospital - Darlinghurst
Query!
Recruitment hospital [5]
0
0
Taylor Square Private Clinic - Darlinghurst
Query!
Recruitment hospital [6]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [7]
0
0
Sexual Health and HIV Service - Clinic 2 - Brisbane
Query!
Recruitment hospital [8]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [9]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment hospital [10]
0
0
Melbourne Sexual Health Centre - Melbourne
Query!
Recruitment hospital [11]
0
0
Prahran Market Clinic - Melbourne
Query!
Recruitment hospital [12]
0
0
Centre Clinic - St Kilda
Query!
Recruitment hospital [13]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2134 - Burwood
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
4000 - Brisbane
Query!
Recruitment postcode(s) [5]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [7]
0
0
3053 - Melbourne
Query!
Recruitment postcode(s) [8]
0
0
3181 - Melbourne
Query!
Recruitment postcode(s) [9]
0
0
3182 - St Kilda
Query!
Recruitment postcode(s) [10]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oregon
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Virginia
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Wisconsin
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Buenos Aires
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Santa Fe
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Cordoba
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Neuquen
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Vienna
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Antwerp
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Brussels
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Ghent
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Leuven
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
BA
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
ES
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
RJ
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
SP
Query!
Country [35]
0
0
Chile
Query!
State/province [35]
0
0
Santiago
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Plzen
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Prague
Query!
Country [38]
0
0
Denmark
Query!
State/province [38]
0
0
Aarhus
Query!
Country [39]
0
0
Denmark
Query!
State/province [39]
0
0
Copenhagen
Query!
Country [40]
0
0
Denmark
Query!
State/province [40]
0
0
Hvidovre
Query!
Country [41]
0
0
Denmark
Query!
State/province [41]
0
0
Odense
Query!
Country [42]
0
0
Estonia
Query!
State/province [42]
0
0
Tallinn
Query!
Country [43]
0
0
Finland
Query!
State/province [43]
0
0
Helsinki
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Besancon
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Caen
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Clamart
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Creteil
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Le Kremlin-Bicetre
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Paris
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Suresnes
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Tourcoing
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Berlin
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Bonn
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Cologne
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Dortmund
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Duesseldorf
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Erlangen
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Essen
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Frankfurt
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Hamburg
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Hanover
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Heidelberg
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Munich
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Regensburg
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Wuerzburg
Query!
Country [66]
0
0
Greece
Query!
State/province [66]
0
0
Athens
Query!
Country [67]
0
0
Greece
Query!
State/province [67]
0
0
Thessaloniki
Query!
Country [68]
0
0
India
Query!
State/province [68]
0
0
Maharashtra
Query!
Country [69]
0
0
India
Query!
State/province [69]
0
0
Tamil Nadu
Query!
Country [70]
0
0
Ireland
Query!
State/province [70]
0
0
Dublin
Query!
Country [71]
0
0
Israel
Query!
State/province [71]
0
0
Haifa
Query!
Country [72]
0
0
Israel
Query!
State/province [72]
0
0
Tel Aviv
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
MI
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
RM
Query!
Country [75]
0
0
Luxembourg
Query!
State/province [75]
0
0
Luxembourg
Query!
Country [76]
0
0
Malaysia
Query!
State/province [76]
0
0
Federal Territory
Query!
Country [77]
0
0
Mali
Query!
State/province [77]
0
0
Bamako
Query!
Country [78]
0
0
Mexico
Query!
State/province [78]
0
0
Tlalpan
Query!
Country [79]
0
0
Morocco
Query!
State/province [79]
0
0
Casablanca
Query!
Country [80]
0
0
Nigeria
Query!
State/province [80]
0
0
FCT
Query!
Country [81]
0
0
Norway
Query!
State/province [81]
0
0
Oslo
Query!
Country [82]
0
0
Peru
Query!
State/province [82]
0
0
Lima
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Bialystok
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Warsaw
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Wroclaw
Query!
Country [86]
0
0
Portugal
Query!
State/province [86]
0
0
Lisbon
Query!
Country [87]
0
0
Portugal
Query!
State/province [87]
0
0
Oporto
Query!
Country [88]
0
0
Puerto Rico
Query!
State/province [88]
0
0
Rio Piedras
Query!
Country [89]
0
0
Puerto Rico
Query!
State/province [89]
0
0
San Juan
Query!
Country [90]
0
0
South Africa
Query!
State/province [90]
0
0
Cape Town
Query!
Country [91]
0
0
South Africa
Query!
State/province [91]
0
0
Durban
Query!
Country [92]
0
0
South Africa
Query!
State/province [92]
0
0
Johannesburg
Query!
Country [93]
0
0
South Africa
Query!
State/province [93]
0
0
Pretoria
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Alcala de Henares
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Badalona
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Barcelona
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Madrid
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Terrassa
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Valencia
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Vigo
Query!
Country [101]
0
0
Sweden
Query!
State/province [101]
0
0
Gothenburg
Query!
Country [102]
0
0
Sweden
Query!
State/province [102]
0
0
Malmo
Query!
Country [103]
0
0
Switzerland
Query!
State/province [103]
0
0
Basel
Query!
Country [104]
0
0
Switzerland
Query!
State/province [104]
0
0
Bern
Query!
Country [105]
0
0
Switzerland
Query!
State/province [105]
0
0
Geneva
Query!
Country [106]
0
0
Switzerland
Query!
State/province [106]
0
0
Zurich
Query!
Country [107]
0
0
Thailand
Query!
State/province [107]
0
0
Bangkok Noi
Query!
Country [108]
0
0
Thailand
Query!
State/province [108]
0
0
Bangkok
Query!
Country [109]
0
0
Thailand
Query!
State/province [109]
0
0
Chiang Mai
Query!
Country [110]
0
0
Thailand
Query!
State/province [110]
0
0
Chiang Rai
Query!
Country [111]
0
0
Thailand
Query!
State/province [111]
0
0
Chon Buri
Query!
Country [112]
0
0
Thailand
Query!
State/province [112]
0
0
Khon Kaen
Query!
Country [113]
0
0
Thailand
Query!
State/province [113]
0
0
Nonthaburi
Query!
Country [114]
0
0
Uganda
Query!
State/province [114]
0
0
Entebbe
Query!
Country [115]
0
0
Uganda
Query!
State/province [115]
0
0
Kampala
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Berkshire
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Cleveland
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Dorset
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
East Sussex
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Leicestershire
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Northern Ireland
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
South Yorkshire
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
West Midlands
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Bristol
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Gloucester
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
London
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
University of Minnesota
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Government body
Query!
Name [1]
0
0
National Institute of Allergy and Infectious Diseases (NIAID)
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Government body
Query!
Name [3]
0
0
Medical Research Council
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
The Kirby Institute for Infection and Immunity in Society
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Government body
Query!
Name [5]
0
0
Washington D.C. Veterans Affairs Medical Center
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Other collaborator category [6]
0
0
Government body
Query!
Name [6]
0
0
ANRS, Emerging Infectious Diseases
Query!
Address [6]
0
0
Query!
Country [6]
0
0
Query!
Other collaborator category [7]
0
0
Government body
Query!
Name [7]
0
0
German Federal Ministry of Education and Research
Query!
Address [7]
0
0
Query!
Country [7]
0
0
Query!
Other collaborator category [8]
0
0
Other
Query!
Name [8]
0
0
NEAT - European AIDS Treatment Network
Query!
Address [8]
0
0
Query!
Country [8]
0
0
Query!
Other collaborator category [9]
0
0
Other
Query!
Name [9]
0
0
National Health and Medical Research Council, Australia
Query!
Address [9]
0
0
Query!
Country [9]
0
0
Query!
Other collaborator category [10]
0
0
Government body
Query!
Name [10]
0
0
National Institutes of Health Clinical Center (CC)
Query!
Address [10]
0
0
Query!
Country [10]
0
0
Query!
Other collaborator category [11]
0
0
Government body
Query!
Name [11]
0
0
National Cancer Institute (NCI)
Query!
Address [11]
0
0
Query!
Country [11]
0
0
Query!
Other collaborator category [12]
0
0
Government body
Query!
Name [12]
0
0
National Heart, Lung, and Blood Institute (NHLBI)
Query!
Address [12]
0
0
Query!
Country [12]
0
0
Query!
Other collaborator category [13]
0
0
Government body
Query!
Name [13]
0
0
National Institute of Mental Health (NIMH)
Query!
Address [13]
0
0
Query!
Country [13]
0
0
Query!
Other collaborator category [14]
0
0
Government body
Query!
Name [14]
0
0
National Institute of Neurological Disorders and Stroke (NINDS)
Query!
Address [14]
0
0
Query!
Country [14]
0
0
Query!
Other collaborator category [15]
0
0
Government body
Query!
Name [15]
0
0
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Query!
Address [15]
0
0
Query!
Country [15]
0
0
Query!
Other collaborator category [16]
0
0
Commercial sector/industry
Query!
Name [16]
0
0
Abbott
Query!
Address [16]
0
0
Query!
Country [16]
0
0
Query!
Other collaborator category [17]
0
0
Commercial sector/industry
Query!
Name [17]
0
0
Bristol-Myers Squibb
Query!
Address [17]
0
0
Query!
Country [17]
0
0
Query!
Other collaborator category [18]
0
0
Commercial sector/industry
Query!
Name [18]
0
0
Gilead Sciences
Query!
Address [18]
0
0
Query!
Country [18]
0
0
Query!
Other collaborator category [19]
0
0
Commercial sector/industry
Query!
Name [19]
0
0
GlaxoSmithKline
Query!
Address [19]
0
0
Query!
Country [19]
0
0
Query!
Other collaborator category [20]
0
0
Commercial sector/industry
Query!
Name [20]
0
0
Merck Sharp & Dohme LLC
Query!
Address [20]
0
0
Query!
Country [20]
0
0
Query!
Other collaborator category [21]
0
0
Commercial sector/industry
Query!
Name [21]
0
0
Tibotec Pharmaceutical Limited
Query!
Address [21]
0
0
Query!
Country [21]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Objectives: * To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is good evidence for starting medicines. * To learn more about how a strategy of starting HIV medicines early might affect other aspects of care, such as the chances of developing other illnesses or resistance to HIV medicines, the frequency of doctor visits, the cost of medical care, and general health and satisfaction.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00867048
Query!
Trial related presentations / publications
Babiker AG, Emery S, Fatkenheuer G, Gordin FM, Grund B, Lundgren JD, Neaton JD, Pett SL, Phillips A, Touloumi G, Vjechaj MJ; INSIGHT START Study Group. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials. 2013;10(1 Suppl):S5-S36. doi: 10.1177/1740774512440342. Epub 2012 Apr 30. INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fatkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. Gabrielaite M, Bennedbaek M, Zucco AG, Ekenberg C, Murray DD, Kan VL, Touloumi G, Vandekerckhove L, Turner D, Neaton J, Lane HC, Safo S, Arenas-Pinto A, Polizzotto MN, Gunthard HF, Lundgren JD, Marvig RL. Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. J Infect Dis. 2021 Dec 15;224(12):2053-2063. doi: 10.1093/infdis/jiab253. Ghazi L, Baker JV, Sharma S, Jain MK, Palfreeman A, Necsoi C, Murray DD, Neaton JD, Drawz PE. Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. Am J Hypertens. 2020 Jan 1;33(1):43-52. doi: 10.1093/ajh/hpz132. Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, Barbosa de Souza M, Phillips AN; INSIGHT START Study Group. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS. 2019 Dec 1;33(15):2337-2350. doi: 10.1097/QAD.0000000000002359. Wyman Engen N, Huppler Hullsiek K, Belloso WH, Finley E, Hudson F, Denning E, Carey C, Pearson M, Kagan J. A randomized evaluation of on-site monitoring nested in a multinational randomized trial. Clin Trials. 2020 Feb;17(1):3-14. doi: 10.1177/1740774519881616. Epub 2019 Oct 24. Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Sharma S, Baker JV, Collins S, Mannheimer S, Pett S, Touzeau-Romer V, Polizzotto MN, Lundgren JD, Gardner EM; INSIGHT START Study Group. Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. J Int AIDS Soc. 2019 Jun;22(6):e25297. doi: 10.1002/jia2.25297. Borges AH, Neuhaus J, Sharma S, Neaton JD, Henry K, Anagnostou O, Staub T, Emery S, Lundgren JD; INSIGHT SMART; START Study Groups. The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. J Infect Dis. 2019 Jan 7;219(2):254-263. doi: 10.1093/infdis/jiy442. Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV. 2018 Apr;5(4):e172-e180. doi: 10.1016/S2352-3018(18)30003-1. Epub 2018 Jan 16. Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, Ndembi N, Lundgren JD, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Treatment (START) Study Group. Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. J Infect Dis. 2018 Jan 17;217(3):405-412. doi: 10.1093/infdis/jix350. Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwarze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group. Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am Heart Assoc. 2017 May 22;6(5):e004987. doi: 10.1161/JAHA.116.004987. Grady C, Touloumi G, Walker AS, Smolskis M, Sharma S, Babiker AG, Pantazis N, Tavel J, Florence E, Sanchez A, Hudson F, Papadopoulos A, Emanuel E, Clewett M, Munroe D, Denning E; INSIGHT START Informed Consent Substudy Group. A randomized trial comparing concise and standard consent forms in the START trial. PLoS One. 2017 Apr 26;12(4):e0172607. doi: 10.1371/journal.pone.0172607. eCollection 2017. O'Connor J, Vjecha MJ, Phillips AN, Angus B, Cooper D, Grinsztejn B, Lopardo G, Das S, Wood R, Wilkin A, Klinker H, Kantipong P, Klingman KL, Jilich D, Herieka E, Denning E, Abubakar I, Gordin F, Lundgren JD; INSIGHT START study group. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per muL: secondary outcome results from a randomised controlled trial. Lancet HIV. 2017 Mar;4(3):e105-e112. doi: 10.1016/S2352-3018(16)30216-8. Epub 2017 Jan 5. Larson GS, Carey C, Grarup J, Hudson F, Sachi K, Vjecha MJ, Gordin F; INSIGHT Group. Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials. Clin Trials. 2016 Apr;13(2):127-36. doi: 10.1177/1740774515625974. Epub 2016 Feb 8. Carr A, Grund B, Neuhaus J, Schwartz A, Bernardino JI, White D, Badel-Faesen S, Avihingsanon A, Ensrud K, Hoy J; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):137-46. doi: 10.1111/hiv.12242. Matthews GV, Neuhaus J, Bhagani S, Mehta SH, Vlahakis E, Doroana M, Naggie S, Arenas-Pinto A, Peters L, Rockstroh JK; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:129-36. doi: 10.1111/hiv.12241. Kunisaki KM, Niewoehner DE, Collins G, Nixon DE, Tedaldi E, Akolo C, Kityo C, Klinker H, La Rosa A, Connett JE; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Pulmonary function in an international sample of HIV-positive, treatment-naive adults with CD4 counts > 500 cells/muL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 0):119-28. doi: 10.1111/hiv.12240. Baker JV, Engen NW, Huppler Hullsiek K, Stephan C, Jain MK, Munderi P, Pett S, Duprez D; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):109-18. doi: 10.1111/hiv.12239. Wright EJ, Grund B, Cysique LA, Robertson KR, Brew BJ, Collins G, Shlay JC, Winston A, Read TR, Price RW; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:97-108. doi: 10.1111/hiv.12238. Lifson AR, Grandits GA, Gardner EM, Wolff MJ, Pulik P, Williams I, Burman WJ; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):88-96. doi: 10.1111/hiv.12237. Baxter JD, Dunn D, White E, Sharma S, Geretti AM, Kozal MJ, Johnson MA, Jacoby S, Llibre JM, Lundgren J; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):77-87. doi: 10.1111/hiv.12236. Rodger AJ, Lampe FC, Grulich AE, Fisher M, Friedland G, Phanuphak N, Bogner JR, Pereira LC, Rietmeijer C, Burman W, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 0):64-76. doi: 10.1111/hiv.12235. Achhra AC, Mocroft A, Ross MJ, Ryom L, Lucas GM, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell JM, Wyatt CM; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Kidney disease in antiretroviral-naive HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):55-63. doi: 10.1111/hiv.12234. Soliman EZ, Sharma S, Arasteh K, Wohl D, Achhra A, Tambussi G, O'Connor J, Stein JH, Duprez DA, Neaton JD, Phillips A; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 0):46-54. doi: 10.1111/hiv.12233. Law MG, Achhra A, Deeks SG, Gazzard B, Migueles SA, Novak RM, Ristola M; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):37-45. doi: 10.1111/hiv.12232. Sharma S, Babiker AG, Emery S, Gordin FM, Lundgren JD, Neaton JN, Bakowska E, Schechter M, Wiselka MJ, Wolff MJ; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):30-6. doi: 10.1111/hiv.12231. Denning E, Sharma S, Smolskis M, Touloumi G, Walker S, Babiker A, Clewett M, Emanuel E, Florence E, Papadopoulos A, Sanchez A, Tavel J, Grady C; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):24-9. doi: 10.1111/hiv.12230. Grarup J, Rappoport C, Engen NW, Carey C, Hudson F, Denning E, Sharma S, Florence E, Vjecha MJ; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(Suppl Suppl 1):14-23. doi: 10.1111/hiv.12229. Geffen N, Aagaard P, Corbelli GM, Meulbroek M, Peavy D, Rappoport C, Schwarze S, Collins S; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Community Advisory Board. Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):10-3. doi: 10.1111/hiv.12228. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fatkenheuer G, Molina JM, Wood R, Neaton JD. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. No abstract available. Kunisaki KM, Quick H, Baker JV. HIV antiretroviral therapy reduces circulating surfactant protein-D levels. HIV Med. 2011 Oct;12(9):580-1. doi: 10.1111/j.1468-1293.2011.00920.x. No abstract available.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
James D Neaton, PhD
Query!
Address
0
0
University of Minnesota
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol, Statistical Analysis Plan, and Inf...
[
More Details
]
https://cdn.clinicaltrials.gov/large-docs/48/NCT00867048/Prot_SAP_ICF_000.pdf
Statistical analysis plan
Study Protocol, Statistical Analysis Plan, and Inf...
[
More Details
]
https://cdn.clinicaltrials.gov/large-docs/48/NCT00867048/Prot_SAP_ICF_000.pdf
Informed consent form
Study Protocol, Statistical Analysis Plan, and Inf...
[
More Details
]
https://cdn.clinicaltrials.gov/large-docs/48/NCT00867048/Prot_SAP_ICF_000.pdf
Results publications and other study-related documents
Type
Citations or Other Details
Journal
INSIGHT START Study Group; Lundgren JD, Babiker AG...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00867048
Download to PDF